Fennec Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

Jun 15, 2022 / 06:30PM GMT
Robert Andrade - Fennec Pharmaceuticals Inc. - CFO

Hello, and thank you to JMP for inviting us here to the conference. We are Fennec Pharmaceuticals. My name is Robert Andrade. I'm the CFO of the company.

Our first slide will start with the customary safe harbor statements. This deck that you're going to be seeing here can also be found on our website under www.fennecpharma.com. And certainly, if there's any follow-up or questions, feel free to reach out to us.

Start with slide 3. This gives you a snapshot of the company. So, what is Fennec? Fennec, for the greater part of a decade nearly, has been focused on the development of PEDMARK. PEDMARK is for the prevention of cisplatinum-induced ototoxicity. Otherwise, the acronym known is CIO, or hearing loss in children. We have a proposed label with the FDA for the prevention of this CIO in all localized non-metastatic tumors.

To get to where we are today, we have successfully completed two randomized Phase 3 trials. Both have been published. The first one being

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot